206 related articles for article (PubMed ID: 29735818)
21. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
22. Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer.
Kodama H; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Narita T; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
Clin Genitourin Cancer; 2019 Dec; 17(6):e1091-e1098. PubMed ID: 31575477
[TBL] [Abstract][Full Text] [Related]
23. The utility of prostate-specific antigen in the management of advanced prostate cancer.
Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
[TBL] [Abstract][Full Text] [Related]
24. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
[TBL] [Abstract][Full Text] [Related]
25. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
Chuang CK; Wu TL; Tsao KC; Liao SK
J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586
[TBL] [Abstract][Full Text] [Related]
26. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
27. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
28. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.
Hamano I; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
World J Urol; 2019 Nov; 37(11):2365-2373. PubMed ID: 30729312
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant androgen deprivation therapy combined with abiraterone acetate in patients with locally advanced or metastatic prostate cancer: When to perform radical prostatectomy?
Xu Z; Wei F; Wang J; Ma S; Kan Y; Li B; Qi N; Mao L
Cancer Med; 2023 Feb; 12(4):4352-4356. PubMed ID: 36106643
[TBL] [Abstract][Full Text] [Related]
30. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
Wang Y; Xu F; Pan J; Zhu Y; Shao X; Sha J; Wang Z; Cai Y; Liu Q; Dong B; Xue W; Huang Y
BMC Cancer; 2016 May; 16():329. PubMed ID: 27222030
[TBL] [Abstract][Full Text] [Related]
31. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
32. Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy.
Nguyen-Nielsen M; Liede A; Maegbaek ML; Borre M; Harving N; Hernandez RK; Sørensen HT; Ehrenstein V
Cancer Epidemiol; 2015 Aug; 39(4):623-32. PubMed ID: 26100365
[TBL] [Abstract][Full Text] [Related]
33. [Change of the LHRH analogue in progressive castration-refractory prostate cancer].
Heidenreich A; Porres D; Epplen R; van Erps T; Pfister D
Urologe A; 2012 Sep; 51(9):1282-7. PubMed ID: 22733398
[TBL] [Abstract][Full Text] [Related]
34. Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer.
Fukuoka K; Teishima J; Nagamatsu H; Inoue S; Hayashi T; Mita K; Shigeta M; Kobayashi K; Kajiwara M; Kadonishi Y; Tacho T; Matsubara A
Int Urol Nephrol; 2020 Jan; 52(1):77-85. PubMed ID: 31552574
[TBL] [Abstract][Full Text] [Related]
35. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.
Strum SB; Scholz MC; McDermed JE
Oncologist; 2000; 5(1):45-52. PubMed ID: 10706649
[TBL] [Abstract][Full Text] [Related]
36. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.
Mirhadi AJ; Zhang Q; Hanks GE; Lepor H; Grignon DJ; Peters CA; Rosenthal SA; Zeitzer K; Radwan JS; Lawton C; Parliament MB; Reznik RS; Sandler HM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):511-515. PubMed ID: 28126300
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
[TBL] [Abstract][Full Text] [Related]
38. The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer.
Iacovelli R; Ciccarese C; Caffo O; De Giorgi U; Basso U; Tucci M; Mosillo C; Maruzzo M; Maines F; Casadei C; Milella M; Tortora G
Anticancer Res; 2022 Jan; 42(1):165-172. PubMed ID: 34969722
[TBL] [Abstract][Full Text] [Related]
39. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
[TBL] [Abstract][Full Text] [Related]
40. Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer.
Nakanishi S; Goya M; Tamaki M; Oshiro T; Saito S
BMC Res Notes; 2021 Jun; 14(1):227. PubMed ID: 34082809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
